Hospital
Largo Medical Center, INC.
Largo Medical Center, INC. was paid $9.62M by Medicaid between Jan 2018 and Dec 2024, across 159 billing codes. Its largest line is 99283, emergency room visit (moderate) — 36% of everything it billed.
33Billing provider infoLARGO MEDICAL CENTER, INC.
LARGO, FL 33770
LARGO, FL 33770
33aNPI1144274879assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.62M
24GClaims497,412
24DCodes billed159
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#54 of 163
Median peer was paid$4.77M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,628 | $355K | |
| 2019 | 103,256 | $1.20M | |
| 2020 | 82,838 | $1.02M | |
| 2021 | 105,860 | $2.10M | |
| 2022 | 100,756 | $2.61M | |
| 2023 | 51,546 | $1.64M | |
| 2024incomplete | 17,528 | $705K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 36% | 42,819 | 37,680 | $3.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 27,620 | 22,393 | $1.30M |
| 80053 | Comprehensive metabolic panel | 8.5% | 34,047 | 23,855 | $817K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 5,440 | 5,048 | $424K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 2,531 | 2,240 | $361K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 5,757 | 4,430 | $350K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.5% | 2,791 | 2,328 | $341K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.0% | 5,414 | 3,851 | $285K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.8% | 1,876 | 1,720 | $170K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.4% | 4,325 | 3,437 | $137K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.3% | 2,688 | 1,970 | $128K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.1% | 2,843 | 188 | $105K |
147 more codes
| 87070 | 1.0% | 7,157 | $99K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,103 | $96K |
| G0378 | Hospital observation service, per hour | <1% | 4,521 | $91K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,436 | $73K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,257 | $71K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 690 | $70K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,419 | $59K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 532 | $57K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 12,252 | $56K |
| 85027 | <1% | 38,545 | $56K | |
| 81001 | <1% | 13,667 | $52K | |
| 81003 | <1% | 9,513 | $40K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,668 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,181 | $39K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,195 | $37K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,788 | $31K |
| A9270 | Non-covered item or service | <1% | 15,995 | $29K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,946 | $27K |
| 83735 | <1% | 10,161 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,328 | $25K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,282 | $25K |
| 81025 | <1% | 7,340 | $24K | |
| 84100 | <1% | 4,530 | $24K | |
| 73610 | <1% | 1,044 | $23K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,430 | $22K |
| 80197 | <1% | 2,907 | $21K | |
| 73562 | <1% | 1,369 | $21K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 153 | $21K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 423 | $21K |
| 82570 | <1% | 2,268 | $19K | |
| 84156 | <1% | 1,868 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,877 | $18K |
| 84702 | <1% | 1,683 | $18K | |
| 73630 | <1% | 1,214 | $17K | |
| 73130 | <1% | 765 | $17K | |
| 87210 | <1% | 1,677 | $17K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 967 | $16K |
| C1769 | Guide wire | <1% | 982 | $16K |
| 73030 | <1% | 902 | $15K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 705 | $14K |
| J3490 | Unclassified drugs | <1% | 818 | $13K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,056 | $13K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,391 | $12K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,106 | $10K |
| 87420 | <1% | 979 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,607 | $10K |
| 12001 | <1% | 123 | $10K | |
| 73110 | <1% | 645 | $10K | |
| 84484 | <1% | 11,207 | $9K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 770 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,456 | $9K |
| 74018 | <1% | 323 | $8K | |
| 93971 | <1% | 327 | $7K | |
| 85610 | <1% | 9,517 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 565 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 358 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,644 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 108 | $5K |
| 84703 | <1% | 4,111 | $5K | |
| 10060 | <1% | 59 | $5K | |
| 80061 | Lipid panel | <1% | 1,778 | $5K |
| 96376 | <1% | 1,774 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 429 | $5K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 919 | $4K |
| 72110 | <1% | 525 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 991 | $4K |
| 73140 | <1% | 129 | $4K | |
| 72131 | <1% | 208 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,929 | $4K |
| 87799 | <1% | 663 | $4K | |
| 87497 | <1% | 308 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,083 | $3K |
| 85730 | <1% | 4,103 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,844 | $3K |
| 12011 | <1% | 60 | $3K | |
| 83690 | <1% | 8,305 | $3K | |
| 86850 | <1% | 1,270 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,496 | $3K |
| 86832 | <1% | 233 | $3K | |
| 73502 | <1% | 159 | $3K | |
| 87186 | <1% | 2,157 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,464 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,525 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,181 | $2K |
| 86833 | <1% | 227 | $2K | |
| 70486 | <1% | 104 | $2K | |
| 87040 | <1% | 2,535 | $2K | |
| 86900 | <1% | 1,879 | $2K | |
| 97163 | <1% | 222 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,237 | $1K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 109 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,500 | $1K |
| 85379 | <1% | 1,141 | $1K | |
| 71101 | <1% | 28 | $1K | |
| 83970 | <1% | 178 | $1K | |
| 86901 | <1% | 1,875 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,075 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,229 | $996.64 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,782 | $840.51 |
| 71250 | <1% | 16 | $840.23 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 214 | $831.85 |
| 84145 | <1% | 223 | $789.47 | |
| 83880 | <1% | 1,579 | $775.76 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,017 | $754.51 |
| 87205 | <1% | 571 | $730.35 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 65 | $695.57 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,075 | $658.82 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,783 | $656.35 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 228 | $565.28 |
| 82550 | <1% | 1,582 | $527.24 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 990 | $506.77 |
| 99153 | Mod sedat endo service >5yrs | <1% | 17 | $487.29 |
| 99152 | <1% | 126 | $487.29 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 69 | $370.39 |
| 73590 | <1% | 33 | $264.61 | |
| 86140 | <1% | 737 | $262.08 | |
| 90715 | <1% | 350 | $237.64 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 91 | $218.07 |
| 74022 | <1% | 78 | $153.31 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 459 | $121.19 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 588 | $102.66 |
| 82607 | <1% | 46 | $88.61 | |
| 82728 | <1% | 43 | $78.05 | |
| 83540 | <1% | 46 | $64.25 | |
| 82746 | <1% | 43 | $59.49 | |
| 83605 | <1% | 1,646 | $51.49 | |
| 82150 | <1% | 28 | $37.80 | |
| 85652 | <1% | 239 | $37.67 | |
| 87147 | <1% | 117 | $29.71 | |
| 86828 | <1% | 58 | $19.80 | |
| 84439 | <1% | 22 | $13.61 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 101 | $13.60 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 665 | $3.32 |
| 82553 | 0% | 14 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 69 | $0.00 |
| 93458 | 0% | 19 | $0.00 | |
| 85007 | 0% | 246 | $0.00 | |
| 80076 | 0% | 17 | $0.00 | |
| 82248 | 0% | 20 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 113 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 83 | $0.00 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 28 | $0.00 |
| 73070 | 0% | 17 | $0.00 | |
| 73080 | 0% | 15 | $0.00 | |
| 90837 | Psychotherapy session, about an hour | 0% | 56 | $0.00 |
| 76937 | 0% | 41 | $0.00 | |
| 93970 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROMIG, GLENN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Central Florida Cardiology Interpretations LLC | Sanford, FL | $62K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.